Quantum Genomics

Quantum Genomics is a biopharmaceutical company developing firibastat, a brain aminopeptidase A inhibitor for the treatment of hypertension and heart failure. Its mechanism is implicated in the 25% of patients resistant to treatment. The Phase IIb study in hypertension was recently very positive and the Phase IIb in heart failure should start in Q219.

Equities

Equities by Sector

Sectors

Thematics

Latest

Hybrid Air Vehicles – Redefining air travel and air freight

The humanoid revolution walking your way: How robots are stepping out of science fiction

From gold to gold miners: Extracting higher returns in the current bull run

Audiovisual

Latest

Mendus – equity proposition

The Law Debenture Corporation in 60 seconds

Team Internet – executive interview

About Edison

About Edison

Careers

Quantum Genomics (PAR: ALQGC)

Latest Insights

Quantum Genomics — Firibastat misses endpoints in Phase III

Quantum Genomics — Steady sailing as FRESH readout approaches

Quantum Genomics — A fresh take on cardiovascular medicine

Quantum Genomics — Phase IIb QUORUM results

Quantum Genomics — Progress in heart failure and controlled release

Quantum Genomics — All set for an eventful 2019

Quantum Genomics — Strong Phase IIb data in hypertension

Quantum Genomics — NEW-HOPE data to be presented at AHA

Quantum Genomics — NEW-HOPE enrolled much faster than expected

Quantum Genomics — A little company going after big indications

Quantum Genomics — The QUORUM trial

Quantum Genomics — Accelerating timelines

Quantum Genomics — NEW-HOPE trial recruiting rapidly

Quantum Genomics — NEW-HOPE trial launched

Quantum Genomics — QGC001 clinical results

Quantum Genomics — Accelerating clinical studies

Quantum Genomics — Update 28 November 2016